The top documents tagged [progression free survival]

Phase-III Studie: HECTOR Topotecan plus Carboplatin (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin) -Intergroup Study of NOGGO und Studiengruppe
Documents Phase-III Studie: HECTOR Topotecan plus Carboplatin (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin) -Intergroup Study of NOGGO und Studiengruppe

222 views

R4 簡聖軒 指導老師: 高志平大夫. Maturation of B lymphocyte DLBCL classification Double hit DLBCL MYC/BCL-2 co-expression DLBCL Conclusion and take home
Documents R4 簡聖軒 指導老師: 高志平大夫. Maturation of B lymphocyte DLBCL classification Double hit DLBCL MYC/BCL-2 co-expression DLBCL Conclusion and take home

242 views

Which difference should we target? Alberto Sobrero Ospedale San Martino IRCCS Genova, Italy
Documents Which difference should we target? Alberto Sobrero Ospedale San Martino IRCCS Genova, Italy

217 views

Ovarian Cancer: Standards of Care and New Opportunities Robert L. Coleman, M.D. Professor & Vice Chair, Clinical Research Department of Gynecologic Oncology
Documents Ovarian Cancer: Standards of Care and New Opportunities Robert L. Coleman, M.D. Professor & Vice Chair, Clinical Research Department of Gynecologic Oncology

222 views

NiCCC (G143) (ENGOT-GYN1) A Randomised Phase II study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma
Documents NiCCC (G143) (ENGOT-GYN1) A Randomised Phase II study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma

228 views

Accelerated Approval Update 2005 Ramzi Dagher, MD DDOP/OODP/CDER/FDA
Documents Accelerated Approval Update 2005 Ramzi Dagher, MD DDOP/OODP/CDER/FDA

238 views

Navigating uncertainty in policy decision making about new cancer drugs: A qualitative study of Canadian policymakers Presenter: Dr. S. Michelle Driedger,
Documents Navigating uncertainty in policy decision making about new cancer drugs: A qualitative study of Canadian policymakers Presenter: Dr. S. Michelle Driedger,

214 views

MULTIPLE MYELOMA ASH 2006 UPDATE Jeffrey Wolf, MD Director, Myeloma Program UCSF
Documents MULTIPLE MYELOMA ASH 2006 UPDATE Jeffrey Wolf, MD Director, Myeloma Program UCSF

220 views

What’s New in HER2: Current Issues in HER2 Positive Breast Cancer Kristine Abueg, RN, MSN, OCN®, CBCN ® Oncology Clinical Trials Kaiser Permanente, Roseville
Documents What’s New in HER2: Current Issues in HER2 Positive Breast Cancer Kristine Abueg, RN, MSN, OCN®, CBCN ® Oncology Clinical Trials Kaiser Permanente, Roseville

217 views

Morton Coleman, M.D. Director, Center for Lymphoma and Myeloma Weill Cornell Medical Center New York Presbyterian Hospital New York, New York Early Stage
Documents Morton Coleman, M.D. Director, Center for Lymphoma and Myeloma Weill Cornell Medical Center New York Presbyterian Hospital New York, New York Early Stage

219 views

High costs of new drugs Carin A. Uyl-de Groot, PhD Professor of health technology assessment iBMG/iMTA, Erasmus University Rotterdam Uyl@bmg.eur.nl Thanks
Documents High costs of new drugs Carin A. Uyl-de Groot, PhD Professor of health technology assessment iBMG/iMTA, Erasmus University Rotterdam [email protected] Thanks

219 views

2012 ALGORITHM FOR MANAGEMENT OF ADVANCED OVARIAN CANCER Bradley J. Monk, MD, FACS, FACOG Professor and Director Division of Gynecologic Oncology Department
Documents 2012 ALGORITHM FOR MANAGEMENT OF ADVANCED OVARIAN CANCER Bradley J. Monk, MD, FACS, FACOG Professor and Director Division of Gynecologic Oncology Department

214 views